VCEL - Vericel Corporation
16.81 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 16.51 |
| Open | 16.61 |
| Bid | 16.75 x 900 |
| Ask | 17.10 x 800 |
| Day's Range | 16.58 - 17.08 |
| 52 Week Range | 8.95 - 21.01 |
| Volume | 501,136 |
| Avg. Volume | 571,092 |
| Market Cap | 738.149M |
| Beta (3Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.08 |
| Earnings Date | Nov 6, 2017 - Nov 10, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.00 |
- Insider Monkey•12 hours ago
Hedge Funds Have Never Been This Bullish On Vericel Corp (VCEL)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- GlobeNewswire•21 days ago
BARDA to Fund NexoBrid Expanded Access Treatment Protocol for Thermal Burns
On May 7, 2019, Vericel announced that it had entered into exclusive license and supply agreements with MediWound Ltd. to commercialize NexoBrid in North America. NexoBrid is a topically-administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial- and full-thickness thermal burns within four hours of application without harming viable tissue. MediWound will receive the additional funding from BARDA under an amendment to an existing BARDA contract. Under the terms of the License Agreement, MediWound will continue to conduct all development activities under the supervision of a Central Steering Committee comprised of members of each party until the BLA is approved and subsequently transferred to Vericel. The NEXT protocol is an open-label, single-arm treatment protocol which allows for the treatment of up to 150 burn patients with deep partial- and full-thickness thermal burns up to 30% of total body surface area. Up to 30 sites will participate in the NEXT protocol. The protocol has been designed to be consistent with current real-life burn treatment practices in the U.S. The increased number of burn centers trained and familiar with NexoBrid prior to FDA approval and commercial availability will improve national readiness for potential burn mass casualty events. To further promote national readiness, the FDA has agreed that in the event of a burn mass casualty event that is not a nationally declared emergency, additional patients could be treated under the NEXT treatment protocol.
- Thomson Reuters StreetEvents•29 days ago
Edited Transcript of VCEL earnings conference call or presentation 7-May-19 12:00pm GMT
Q1 2019 Vericel Corp Earnings Call
- GlobeNewswire•last month
Vericel to Present at the 2019 UBS Global Healthcare Conference on Wednesday, May 22, 2019
CAMBRIDGE, Mass., May 15, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced.
- American City Business Journals•last month
Surgeons to use product from Cambridge's Vericel on baby born without skin
Vericel Corp. said Tuesday that it growing skin grafts for Ja’bari Gray has been intensive care since being born earlier this year with skin only on his head.
- Insider Monkey•last month
Were Hedge Funds Right About Dumping Vericel Corp (VCEL) ?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth […]
Motley Fool•last monthVericel (VCEL) Q1 2019 Earnings Call Transcript
VCEL earnings call for the period ending March 31, 2019.
- American City Business Journals•last month
Vericel looks to market a gel for burns with new $142M licensing deal
The Cambridge firm said Tuesday it will pay $17.5 million upfront and up to $125 million in milestones to license and sell the burn repair product NexoBrid from Israeli company MediWound Ltd.
- GlobeNewswire•last month
Vericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance
MACI Revenue Increased 38% Over First Quarter 2018 Positive Cash Flow in First Quarter Announced Exclusive License Agreement with MediWound for North American Rights to.
- GlobeNewswire•last month
MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has entered into exclusive license and supply agreements with Vericel Corporation (VCEL) to commercialize NexoBrid® in North America (NA). NexoBrid is a topically-administered biologic product that removes eschar in patients with deep partial and full-thickness thermal burns, which is approved in the European Union and other international markets. The pivotal U.S. phase 3 DETECT clinical study met its primary and all secondary endpoints, and the submission of the Biological License Application (BLA) to the U.S. Food and Drug Administration (FDA) is planned for the fourth quarter of 2019.
- GlobeNewswire•last month
Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns
Vericel Corporation (VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it has entered into exclusive license and supply agreements with MediWound Ltd. to commercialize NexoBrid® in North America. NexoBrid is a topically-administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within four hours of application without harming viable tissue. In January 2019, MediWound announced positive top-line results from the pivotal Phase 3 U.S. clinical study (DETECT) of NexoBrid in adult patients with deep partial- and full-thickness thermal burns up to 30% of total body surface area.
- Simply Wall St.•last month
Calculating The Intrinsic Value Of Vericel Corporation (NASDAQ:VCEL)
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! How far off is Vericel Corporation (NASDAQ:VCEL) from its intrinsic value? Using the most recent fina...
- Insider Monkey•last month
Here’s What Hedge Funds Think About Vericel Corp (VCEL)
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth […]
- Zacks•2 months ago
Will Vericel (VCEL) Report Negative Earnings Next Week? What You Should Know
Vericel (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•2 months ago
Vericel to Report First-Quarter 2019 Financial Results on May 7, 2019
CAMBRIDGE, Mass., April 25, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced.
- GlobeNewswire•3 months ago
Vericel to Present at Needham Healthcare Conference
CAMBRIDGE, Mass., April 03, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced.
- GlobeNewswire•3 months ago
Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- Simply Wall St.•3 months ago
Our Take On Vericel Corporation’s (NASDAQ:VCEL) CEO Salary
Nick Colangelo has been the CEO of Vericel Corporation (NASDAQ:VCEL) since 2013. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that,Read More...
- Zacks•3 months ago
What Makes Vericel (VCEL) a New Buy Stock
Vericel (VCEL) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire•4 months ago
Vericel to Present at Multiple Upcoming Investor Conferences
CAMBRIDGE, Mass., March 04, 2019 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of VCEL earnings conference call or presentation 26-Feb-19 1:30pm GMT
Q4 2018 Vericel Corp Earnings Call
Motley Fool•4 months agoVericel Corp (VCEL) Q4 2018 Earnings Conference Call Transcript
VCEL earnings call for the period ending December 31, 2018.
- Zacks•4 months ago
Vericel (VCEL) Tops on Q4 Earnings & Sales, Stock Up
Vericel (VCEL) beat estimates for earnings as well as revenues in fourth-quarter 2018. Shares up in pre-market trading.
- GlobeNewswire•4 months ago
Vericel Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Full-Year 2019 Financial Guidance
Record Quarterly Product Revenues of $31.3 Million Represent a 41% Increase Over Fourth Quarter 2017 Full-Year 2018 Product Revenues of $90.9 Million Conference Call Today at.
